Since the first groundbreaking procedure in 2002, transcatheter aortic valve implantation
(TAVI) has revolutionized the management of aortic stenosis (AS). Through striking …

A shift to lifetime management has gained more focus with the approval of low-risk
transcatheter aortic valve replacement (TAVR). This paper is therefore focused on the …

The use of valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) is increasing, but
studies evaluating clinical outcomes in these patients are scarce. Also, there are limited data …

Transcatheter heart valve technology has rapidly progressed since initial approval in the
United States. There are currently two widely available transcatheter heart valve delivery …

Aims It is not well known if sex differences in the use and results of aortic valve replacement
(AVR) are changing. The aim of the study is to assess the time trends in the differences by …

Highlights What is known? Transcatheter aortic valve replacement (TAVR) has become the
standard of care beside sur-gical valve replacement (SAVR) in the majority of patients with …

Introduction: Bioprosthetic valves (BPV) implanted surgically or by transcatheter valve
implantation (TAVI) comprise an overwhelming majority of substitute aortic valves implanted …

Background As redo surgical aortic valve replacement (AVR) is relatively high risk, valve-in-
valve transcatheter AVR has emerged as an alternative for failed prostheses. However, the …

Objectives The use of bioprosthetic aortic valve replacement (AVR) is inherently associated
with a risk of structural valve degeneration (SVD) and the need for aortic valve (AV) …

The recent years have seen a huge expansion in the number of bioprostheses implanted,
and this number is likely to increase further in the future. This is likely to lead to a pandemic …